CoChat

Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?

Mansur, Rodrigo B., Lee, Yena, Subramaniapillai, Mehala, Brietzke, Elisa, McIntyre, Roger S. · 2018 · Neuropharmacology
Cited by 47

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Major depressive disorder and bipolar disorder are highly prevalent and disabling conditions. Cognition is considered a core domain of their psychopathology and a principle mediator of psychosocial impairment, disproportionately accounting for overall illness‐associated costs. There are few interventions with replicated evidence of efficacy in treating cognitive deficits in mood disorders. Evidence also indicates that cognitive deficits are associated with obesity and involve significant impairment across multiple domains. Conversely, weight‐loss interventions, such as physical exercise and bariatric surgery, have been shown to beneficially affect cognitive function. This convergent phenomenology suggests that currently available agents that target metabolic systems may also be capable of mitigating deficits in cognitive functions, and are, therefore, candidates for repurposing. The incretin glucagon‐like peptide‐1 (GLP‐1) is a hormone secreted by intestinal epithelial cells. GLP‐1 receptors (GLP‐1R) are widely expressed in the central nervous system. Activation of GLP‐1R leads to facilitation of glucose utilization and antiapoptotic effects in various organs. Pre‐clinical trials have demonstrated significant neuroprotective effects of GLP‐1, including protection from cell death, promotion of neuronal differentiation and proliferation; and facilitation of long‐term potentiation. Liraglutide is a GLP‐1R agonist that has been approved for the treatment of type 2 diabetes mellitus and obesity. Convergent preclinical and clinical evidence, including a proof‐of‐concept pilot study from group, has suggested that liraglutide may improve objective measures of cognitive function in adults with mood disorders. The safety and availability of GLP‐1R agonists indicate that they are promising candidates for repurposing, and that they may be viable therapeutic options for mood disorders. This article is part of the Special Issue entitled ‘Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.’ HighlightsCognition is a principle mediator of psychosocial impairment in mood disorders and associated with metabolic disorders.Available agents that target metabolic systemsmay be capable of mitigating cognitive deficits.Liraglutide, a GLP‐1R agonist is approved for the treatment of type 2 diabetes mellitus and obesity.A recent proof‐of‐concept study reported significant improvements on cognitive function with liraglutide in mood disorders.The safety and availability of GLP‐1R agonistsindicate that they may be viable therapeutic options for mood disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2018.01.048

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 47

Metadata

Authors
Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E., & McIntyre, R. S.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2018-07
Volume
136
Issue
Pt B
Pages
335-342
ISSN
0028-3908 (ISSN-L)
OpenAlex
W2789918798
Cited by
47
References
41
FWCI
2.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists? https://app.cochat.ai/papers/10.1016/j.neuropharm.2018.01.048
The paper
Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E., & McIntyre, R. S. (2018). Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists? Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.01.048

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.